Observational Study on Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis at Brest University Hospital

What this Trial Is About

This observational study includes patients diagnosed or followed at Brest University Hospital with Philadelphia negative myeloproliferative neoplasms, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The study aims to collect and analyze clinical and biological data from diagnosis through ongoing follow-up to better understand disease progression and outcomes. Clinical information gathered includes patient and disease characteristics at diagnosis, mutational status, cardiovascular risk factors, and history of thrombosis or cancer. Biological data such as hemogram and bone marrow results are recorded when available. During follow-up, treatment changes and their reasons, thrombotic events, phenotypic changes, and deaths with their causes are noted. Participants are observed until the last update, such as death or change of care center. The main outcome measured is overall survival over 10 years, with secondary outcomes including incidence of disease evolutions and thromboses over the same period. Patients who are alive are asked to sign a consent form to continue in the study.

Myeloproliferative Neoplastic Diseases Observatory From Brest